Breaking News

China September PMI Edges Economists Estimates
Tweet TWEET

OncoGenex to Present at Credit Suisse Healthcare Investor Conference

     OncoGenex to Present at Credit Suisse Healthcare Investor Conference

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2013 /PRNewswire/
--OncoGenex Pharmaceuticals, Inc.(NASDAQ: OGXI) announced today that Scott
Cormack, President and Chief Executive Officer, will provide a corporate
presentation at the Credit Suisse Healthcare Conference on Tuesday, November
12, 2013 at 8:30 a.m. MST at the Phoenician Hotel in Scottsdale, Arizona.

A live audio webcast can be accessed through the Investor Relations page of
the OncoGenex website atwww.oncogenex.com. The webcast replay will be
archived for 60 days.

Highlights from the presentation can be followed on the new OncoGenex Investor
Relations Twitter account at: http://twitter.com/@OncoGenex_IR.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd. have entered a global collaboration and license agreement to
develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen
is currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer and in patients with advanced,
unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical
development and OGX-225 is currently in pre-clinical development. More
information is available at www.OncoGenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.

Website: http://www.OncoGenex.com
Contact: Media Contact: Jaime Welch, jwelch@oncogenex.com, 604-630-5403 or
Investor Relations Contact: Susan Specht, sspecht@oncogenex.com, 425-686-1535
 
Press spacebar to pause and continue. Press esc to stop.